GLP-1 Agonists and Mental Health: What the Evidence Shows

How the safety signal arose

Beginning in 2023, the Icelandic Medicines Agency reported three cases of suicidal ideation in patients on liraglutide or semaglutide. The EMA opened a PRAC review and the FDA opened its own evaluation in parallel. Both agencies followed standard pharmacovigilance methodology: spontaneous adverse-event review, disproportionality analyses in FAERS and EudraVigilance, and review of randomized trial and observational datasets.

FDA April 2024 conclusion

The FDA reviewed semaglutide (Ozempic, Wegovy, Rybelsus), liraglutide (Saxenda, Victoza), and tirzepatide (Mounjaro, Zepbound)¹. After review of FAERS reports, randomized clinical trial data, and large electronic health record studies, the agency concluded that a causal association between GLP-1 receptor agonists and suicidal thoughts or actions was not demonstrated. The Wegovy label retains the warning for mood and behavior changes that has been present since 2021.

EMA PRAC April 2024 conclusion

The EMA PRAC reviewed approximately 150 reports of suicidal ideation or self-harm and found no causal evidence linking GLP-1 use with suicidal thoughts. No label changes were required for the GLP-1 class². Reporting requirements continue.

Randomized trial mood data

STEP-1 through STEP-5 all included patient-reported quality-of-life and mood instruments (SF-36, IWQOL-Lite). Across the program, semaglutide groups showed small numerical improvements in mental component summary scores versus placebo — consistent with the broader literature showing successful weight loss is associated with improvement, not worsening, of depression scores³&sup4;. SURMOUNT-1 reported similar improvements with tirzepatide&sup5;.

Observational evidence

A 2024 cohort study of more than 240,000 patients compared rates of new suicidal ideation between semaglutide-treated patients (for obesity or T2D) and matched patients on alternative medications. The study found no increased risk and, in subgroup analyses, lower rates of new suicidal ideation in the semaglutide group&sup6;. FAERS disproportionality analyses (reporting odds ratio) similarly found no signal for suicidal ideation with GLP-1 agonists relative to other endocrine medications.

Clinical implications

GLP-1 receptor agonists do not currently carry FDA or EMA contraindication or boxed warning for depression or suicidality. The Wegovy label recommends monitoring for mood changes. Patients with a history of major depression should be screened at initiation and counseled to report new or worsening symptoms. Active suicidal ideation or recent suicide attempt is generally considered a contraindication to elective GLP-1 initiation pending psychiatric stabilization. Patients on stable antidepressant therapy with controlled mood symptoms are not excluded by current guidance.

Related editorial coverage

• GLP-1 side effects — detailed overview
• Contraindications to GLP-1 therapy

Frequently asked questions

Does Ozempic, Wegovy, or Mounjaro cause depression?

Current evidence from FDA and EMA reviews and from large randomized trials does not show that GLP-1 receptor agonists cause new depression or worsen mood.

Is there a suicide warning on Wegovy or Ozempic?

Wegovy carries a label warning to monitor for depression, suicidal thoughts, or behaviors, present since 2021. Ozempic does not. FDA and EMA in 2024 did not require additional warnings.

Can I take a GLP-1 with a history of depression?

A history of depression is not a contraindication. Patients with stable, treated depression generally tolerate GLP-1 therapy well. Active or untreated severe depression warrants stabilization first.

Can GLP-1 drugs improve mood?

Trials show small improvements in patient-reported mood scores during GLP-1 weight loss, attributable in part to weight loss itself. These effects are modest and not a substitute for treatment of clinical depression.

What should I do if I notice mood changes?

Report new depression, anxiety, suicidal thoughts, or behavioral changes to your prescriber promptly.